Clinical Trial Update: Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating tandem CAR T cells targeting CD19 and CD22 for relapsed or chemotherapy-refractory B-cell malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia in Remission
• B-cell Adult Acute Lymphoblastic Leukemia
• B-cell Chronic Lymphocytic Leukemia in Relapse
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hematopoietic Lymphoid Cancer
• Mantle Cell Lymphoma
• Prolymphocytic Leukemia

Drugs mentioned

• CD19/CD22 tandem CAR T cells

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1, Phase 2 | Status: UNKNOWN